18F-FDG PET/CT联合Comet实验指导局部晚期宫颈癌同步放化疗的随机对照试验研究方案
BACKGROUND: Cisplatin-based chemoradiation is the standard of care for patients with locally advanced cervical cancer. Nevertheless, an increasing number of radio-resistant tumors still recur.…
要点
- FDG-PET/CT可提高活检与勾画肿瘤体积的一致性。
- Comet实验可作为肿瘤放射敏感性的潜在临床检测。
- RapidArc在靶区覆盖、危及器官保护和缩短治疗时间方面有优势。
核心结论
- 基于FDG-PET/CT和Comet实验可安全给予精确肿瘤体积更高剂量,同时降低膀胱和直肠剂量。
主要发现
- RapidArc在改善靶区覆盖程度、保护危及器官、减少健康组织照射和显著缩短治疗时间方面具有明显优势。
- FDG-PET/CT可提高活检与勾画肿瘤体积之间的一致性,并可能对治疗过程产生积极影响。
- Comet实验作为肿瘤放射敏感性的潜在临床检测具有吸引力。
关键数值与推荐
- 所有患者接受外照射全盆腔放疗和高剂量率腔内近距离放疗,同步每周顺铂30 mg/m2共5程。
- 根据化疗后MRI或PET/CT进行2-4周期TP方案序贯化疗(紫杉醇135 mg/m2 D1,顺铂75 mg/m2 D1-3)。
- 主要终点为无进展生存期,次要终点为总生存期和至进展时间。
临床怎么用
- 在放疗中基于FDG-PET/CT和Comet实验精确勾画肿瘤体积,可安全提升靶区剂量并降低膀胱和直肠受量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cisplatin-based chemoradiation is the standard of care for patients with locally advanced cervical cancer. Nevertheless, an increasing number of radio-resistant tumors still recur. METHODS AND DESIGN: Three hundred cervical cancer patients with FIGO stages IB2-IVA and no para-aortic lymphadenopathy (> 10 mm) will be enrolled. All patients will be randomly divided into four arms to receive either (1) intensity modulated radiation therapy (IMRT), (2) RapidArc, (3) positron emission tomography/computed tomography (PET/CT) with F-18 fluorodeoxyglucose (FDG), or (4) Comet assay-guided IMRT, PET/CT, and Comet assay-guided RapidArc. All patients will receive definitive radiotherapy consisting of external beam whole pelvic radiation therapy and high-dose rate intracavitary brachytherapy. Cisplatin 30 mg/m2 weekly will be administered concurrently for five courses. Two to four cycles of TP (Taxol 135 mg/m2, D1, and DDP 75 mg/m2, D1-3) sequential chemotherapy will be performed according to MRI or PET/CT after cisplatin-based chemoradiation. The primary outcome measure is progression-free survival, and the second outcome measures are overall survival and time to progression. DISCUSSION: RapidArc has an obvious advantage in improving the degree of target coverage, improving organs at risk, sparing healthy tissue, and significantly reducing the treatment time. FDG-PET/CT can increase the agreement between biopsies and delineated tumor volume and has the potential to positively impact the course of treatment. The Comet assay is attractive as a potential clinical test of tumor radiosensitivity. During radiotherapy, accurately defining disease areas is critical to avoid the unnecessary irradiation of normal tissue. Based on FDG-PET/CT and Comet assay, higher doses can be safely delivered to accurate tumor volumes, while the doses to the bladder and rectum are relatively low. TRIAL REGISTRATION: ClinicalTrials.gov Protocol Registration and Results System Receipt Release Date: May 21, 2017 - Retrospectively registered. NCT03163979 .
引用
- Ji S, Hu Q, Zhu J, et al. Combined pretreatment with 18F-FDG PET/CT and Comet assay guides the concurrent chemoradiotherapy of locally advanced cervical cancer: study protocol for a randomized controlled trial. Trials. 2018. PMID: 30075736. doi:10.1186/s13063-018-2800-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。